Bls Pharmaceuticals(ASX) BLS

Market CapA$234.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-24%
5 Year+420%
1 Year+215%
1 Month-12%
A$1.04
+2.46%
+0.02Today
Bls Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 1.042026-10-13
Bls Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.67%AUD 0.982026-10-06
1 month-11.86%AUD 1.182026-09-11
3 month+10.05%AUD 0.952026-07-15
Year to date+147.62%AUD 0.422025-12-31
1 year+215.15%AUD 0.332025-10-13
3 year+766.67%AUD 0.122023-10-13
5 year+420%AUD 0.202021-10-13
Since inception-23.68%AUD 1.332012-04-10

Bls Pharmaceuticals Financials at a Glance

Market Cap

A$234.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

A$0.07

P/E Ratio

14.93

Dividend

A$0.00

Beta (Volatility)

-0.14 (Low)

Price

A$1.04

Volume

193,438

Open

A$1.03

Previous Close

A$1.04

Daily Range

A$1.02 - A$1.05

52-Week Range

A$0.34 - A$1.30

Estimated Earnings Date

N/A

BLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bls Pharmaceuticals

BLS Pharmaceuticals Limited is a dynamic company engaged in the research, development, marketing, and distribution of health products. With a focus on specialty business services, BLS Pharmaceuticals operates through various segments, including Wholesale, Plant Based, and Direct Sales.

Products and Services
  • Wholesale segment operates in the USA and Asia
  • Plant Based segment focuses on manufacturing and distribution
  • Direct Sales segment targets markets in Australia and Asia
Growth Outlook
  • Market expansion in the USA and Asia is underway
  • Increasing demand for plant-based health products is notable
  • Direct Sales segment shows potential for significant growth
Financial Highlights
  • Market capitalization stands at AUD 233.69 million
  • Stock price has ranged from AUD 0.33 to AUD 1.30 in the past year
  • Beta of 0.648 indicates lower volatility compared to the market
BLS Pharmaceuticals Limited is well-positioned in the health products sector, leveraging its diverse operational segments to capture market opportunities. The company's focus on plant-based products aligns with growing consumer trends towards health and sustainability. With a solid market capitalization and a relatively stable stock price, BLS Pharmaceuticals presents an intriguing option for investors interested in the specialty business services industry. The ongoing expansion efforts in key markets further enhance the company's growth potential, making it a noteworthy entity in the health products landscape.
AI Generated • Oct 3, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Sam Watson

Website

www.bioxyne.com

Headquarters

Sydney, NSW 2000, AU

BLS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

70.80%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

6.70%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

A$234.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

230.96M

Volume

193.44K

Avg. Volume

313.29K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Bls Pharmaceuticals Performance Analysis

Bls Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 5,154,4151011.7%
20242024-06-30AUD 9,325,02080.9%
20252025-06-30AUD 28,429,544204.9%
20262026-06-30AUD 74,164,632160.9%
Bls Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01114.9%
20242024-06-30AUD -0.07377.8%
20252025-06-30AUD 0.02N/A
20262026-06-30AUD 0.07193.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

A$234.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MYX.AXMayne Pharma Group Limited
A$2.54+0.79%
VLS.AXVita Life Sciences Limited
A$2.84+0.71%
BIO.AXBiome Australia Limited
A$0.41-2.41%
LGP.AXLittle Green Pharma Ltd
A$0.07-2.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$15.74-11.82%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.19+8.14%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$128.40-8.13%
NOKNokia
$9.90-4.44%

Questions About BLS

What is the current price of Bls Pharmaceuticals?

Bls Pharmaceuticals is trading at A$1.04 per share.

What is the 52-week range for Bls Pharmaceuticals?

Over the past 52 weeks, Bls Pharmaceuticals has traded between A$0.34 and A$1.30.

How much debt does Bls Pharmaceuticals have?

As of the most recent reporting period, Bls Pharmaceuticals reported total debt of A$8.43M.

How much cash does Bls Pharmaceuticals have on hand?

Bls Pharmaceuticals reported A$13.29M in cash and cash equivalents in its most recent financial results.

What is Bls Pharmaceuticals’s dividend yield?

Bls Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services